High grade leiomyosarcoma mimicking a recurrent angiomyxoma in the perineum

Neha Sood,1 Abhishek Swaika,2 Bashar Hanooshi,3 James Waldorf,4 Jennifer Peterson,3 Kevin Wu,6 Steven Atta,2 Tri A. Dinh1
1Department of Medical and Surgical Gynecology, 2Department of Medicine, Mayo Clinic Florida, Jacksonville, FL; 3Department of Obstetrics and Gynecology, Flushing Hospital Medical Center, New York City, NY; 4Department of Plastic Surgery, 5Department of Radiation Oncology, 6Department of Pathology, Mayo Clinic Florida, Jacksonville, FL, USA

Abstract

Perineal leiomyosarcoma is an extremely rare and aggressive cancer with a high metastatic potential and no defined standard treatment. There are only a few (six) reported cases in the literature. We report the case of a 67-year-old woman with a perineal leiomyosarcoma arising at the same site of a previously resected superficial angiomyxoma. Initially, she was treated for a presumptive recurrence of angiomyxoma. As she did not respond to medical therapy, she underwent repeat surgical excision. Pathology revealed a high grade leiomyosarcoma, histologically strikingly distinct from the initial diagnosis. She received adjuvant local radiation therapy, and remains without evidence of recurrent disease 36 months after completion of all therapy. This is the first reported case of a high grade perineal leiomyosarcoma originating at the same site as a resected benign superficial angiomyxoma. Our case emphasizes the necessity of a prompt histological diagnosis in cases of presumed recurrent perineal angiomyxoma.

Case Report

A 67-year-old Caucasian female presented to our clinic for the management of a recurrent perineal mass. Fourteen months prior, she had similar complaints and was diagnosed with superficial angiomyxoma of the perineum after surgical resection of the mass from the left paravaginal and pararectal space. The margins were negative. Immunohistochemistry of this 5x3x2.5 cm benign myxoid lesion was positive for smooth muscle actin and estrogen receptor, and negative for desmin and caldesmon. A diagnosis of superficial angiomyxoma was made (Figure 1). Two months after the procedure, she noted swelling with pain at the surgical site. A magnetic resonance imaging (MRI) of the pelvis confirmed a recurrent mass (6.4x6.2x8.5 cm) at the same site and was presumed to be a recurrent angiomyxoma. Biopsy was not obtained. The patient was started on anti-estrogen therapy with tamoxifen. She was continued on tamoxifen for a total of 8 months with very minimal resolution of her clinical symptoms. A repeated MRI revealed increasing size of the mass, for which she was switched to an aromatase inhibitor, letrozole. The patient was referred to our facility after 6 weeks of letrozole did not seem to provide any clinical or radiological benefit. The patient had a history of uterine leiomyoma for which she underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy twenty-two years prior to this present presentation. She also had a history of vaginal dysplasia and was treated with excision sixteen years prior to presentation. At our first clinical visit, the patient complained of persistent pain in her perineal region, with noticeable discomfort in a seated position. She denied complaints with bladder or bowel habits. She denied any weight loss, fever or vaginal bleeding. A recto-vaginal examination revealed a large mass within the perineum, extending into the buttocks. MRI demonstrated a hypervascular, well circumscribed 9.8x8.1x8.8 cm ischioanal fossa tumor with considerable mass effect on adjacent structures but without invasion (Figure 2). Pelvic lymph nodes were not involved radiologically and the metastatic workup was negative.

The presumptive radiological diagnosis was recurrent angiomyxoma. She underwent embolization of the feeding vessels prior to the surgical resection, which involved a complete excision of the mass without entry into the capsule of the tumor. There was no local invasion of any surrounding structures. This was followed by a gracilis muscle flap closure of the resultant perineal defect. The resected tumor measured 11.5x10.0x9.5 cm and weighed 402 grams. Histopathology revealed a high grade spindle cell neoplasm characterized by marked cellular and pleomorphism with increased mitotic activity (>5 per 10 high power fields) and areas of necrosis (Figure 3). Immunohistochemistry showed positive immunoreactivity of the tumor cells for actin and desmin while S-100, CD117 and keratin AE1/AE3 were negative, confirming the diagnosis of a high grade leiomyosarcoma. The anal margin was involved by tumor. The previously excised specimen from 14 months ago was compared to the current tumor with the former demonstrating a multilobulated hypocellular tumor with circumscribed borders composed of bland stellate and spindled cells in a loose stroma with scattered thin walled vessels and sparse inflammation consistent with a diagnosis of superficial angiomyxoma (Figure 1). No atypia, increased mitotic activity or necrosis was present. She underwent adjuvant radiation therapy receiving 60 Gray in 30 fractions to the post-operative bed involving the left perineum and pelvis followed by a boost of 6 Gray in 3 fractions to the area of positive margin along the anal canal (total dose: 66 Gray in 33 fractions.) She was also offered adjuvant chemotherapy with Adriamycin and Ifosfamide, which she declined. She has had close follow-up clinical exams and imaging for the last 36 months, without any recurrence of her disease.

Discussion

Soft tissue sarcomas are rare cancers with an annual incidence of less than 5 per 1,000,000.1 This comprises 0.7-1% of all cancers diagnosed annually, with leiomyosarcoma being one of the most common. As per the SEER data, higher incidences of leiomyosarcomas were noted in white females. Advanced grade, stage and age at diagnosis were independent markers of poor survival. The uterus and retroperitoneum were reported to be the most common anatomical sites involved.

Perineal leiomyosarcoma represents a very rare entity and an extensive search of the English literature reveals only a few documented case reports.2,4 These are aggressive tumors with no defined standard treatment protocol. Complete surgical excision is considered the
treatment of choice, irrespective of the histological grade. The close proximity of these tumors to multiple vital organs often prevents complete resection with negative surgical margins. Adjuvant radiotherapy becomes imperative especially in cases with positive margins. The role of adjuvant chemotherapy is not well defined. Prospective clinical trials examining the use of adjuvant chemotherapy and/or radiation therapy are needed to validate their use in treatment of these rare tumors of the perineum.

The role of Positron emission tomography-computed tomography (PET-CT) scans in post-therapy surveillance to detect recurrence in asymptomatic patients with history of uterine leiomyosarcoma showed promising results. MRI seems to be the best diagnostic tool to characterize these lesions. Radiologically, leiomyosarcomas commonly present as soft tissue masses with low intermediate signal intensity on T1 weighted images and high signal intensity on T2 weighted images.

Histologically, they are composed of highly cellular fascicles of spindle shaped cells and elongated nuclei with blunted cigar shaped appearance. Mitotic figures are generally seen throughout the lesion. The presence of high cellularity, significant nuclear atypia, necrosis, and at least 1 mitotic figure per 10 high power fields, are indicative of a malignant smooth muscle neoplasm. On the other hand, superficial angiomyxoma is a mesenchymal lesion with abundant mucin-rich myxoid matrix and a sparse population of stellate and spindle cells without significant atypia. They generally have lobular or multinodular architecture with minimal mitotic activity. Mostly curvilinear thin-walled, capillary like blood vessels are present. Mixed inflammation including presence of neutrophils may be present. These lesions are positively immunoreactive for actin and CD34, while generally being negative for caldesmon and desmin. They may also variably express estrogen and progesterone receptors. Radiologically they can sometimes be indistinguishable from a high grade malignancy. Complete surgical resection remains the treatment of choice for angiomyxomas, though there is a tendency for local recurrence. There has been some benefit with anti-estrogen therapy used as definitive treatment for primary and recurrent aggressive angiomyxomas. They have also been used in the neo-adjuvant setting to reduce tumor volume especially for those arising in difficult locations where surgical resection remains a challenge. Use of hormonal agents has also been tried in the adjuvant setting after resection of the primary or recurrent angiomyxoma. Both the Gonadotropin-releasing hormone analogs and the aromatase inhibitors have been used, with the choice of agent depending on the menopausal status of
the patient. However, these treatment choices have not yet been studied prospectively and most cases have a history of aggressive angiomyxomas and not superficial angiomyxoma. Thus, a prompt histological diagnosis of any such presumed recurrent angiomyxoma becomes imperative. More recently, analysis of microRNA expression profiling and the discovery of high frequency of Pten mutations and its role in genomic instability have been described in leiomyosarcomas. Molecular and proteomic analysis along with screening for alterations in Pten genes, will now provide us with an opportunity to improve the classification of soft tissue tumors, better predict the outcomes and personalize therapy with the help of specific small tumors, better predict the outcomes and personalized therapy with the help of specific small tumours, better predict the outcomes and personalized therapy with the help of specific small tumours.

Several clinical trials are underway to address these questions. This might be beneficial in our patient in the future, in case of local or distant recurrence. No such mutational analysis has been studied in benign superficial angiomyxomas. It is highly unlikely that these two histologically distinct tumors have a similar cell of origin.

Conclusions

To the best of our knowledge, this is the first reported case of a high grade perineal leiomyosarcoma originating at the same site of a resected benign superficial angiomyxoma. Our case also emphasizes the necessity of a prompt histological diagnosis in cases of presumed recurrent perineal angiomyxomas. It also challenges the role of any adjuvant chemotherapy in cases of leiomyosarcoma.

References

1. Ng VY, Scharschmidt TJ, Mayerson JL, Fisher JL. Incidence and survival in sarcoma in the United States: a focus on musculoskeletal lesions. Anticancer Res 2013;33:2597-604.
2. Rice JP, MacGillivray DC, Sharpe RW, et al. Perineal leiomyosarcoma. Gynecol Oncol 1990;37:132-7.
3. Me in C, Vasile I, Vîlcea ID, et al. Axillary and perianal leiomyosarcoma: report of two cases. Rom J Morphol Embryol 2010;51:379-85.
4. Guven ESG, Guven S, Esin S, et al. Recurrent extraperitoneal low grade leiomyosarcoma with unusual localization. Eur J Gynaecol Oncol 2004;25:381-3.
5. Grove A, Backman Nohr S. Superfi cial perineal leiomyosarcoma in an adolescent female and a review of the literature including vulvar leiomyosarcomas. APMS 1992;100:1081-8.
6. de Lima MA, Pozzobon BHZ, Fonseca MFM, et al. Perineal leiomyosarcoma: case report and literature review. Rev Brasil Coloproctol 2010;30:352-5.
7. Park JY, Kim EN, Kim DY, et al. Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. Gynecol Oncol 2008;109:255-62.
8. Vliet M, Kliffen GP, Krestin GP, Dijke CF. Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors. Eur Radiol 2009;19:1499-511.
9. Hashimoto H, Daimaru Y, Tsuneyoshi M, Enjoji M. Leiomyosarcoma of the external soft tissues. A clinicopathologic, immunohistochemical, and electron microscopic study. Cancer 1986;57:2077-88.
10. Hornick JL, Fletcher CDM. Criteria for malignancy in nonvisceral smooth muscle tumors. Ann Diagn Pathol 2003;7:60-6.
11. McCluggage WG. A review and update of morphologically bland vulvovaginal mesenchymal lesions. Int J Gynecol Pathol 2005;24:26-38.
12. Outwater EK, Marchetto BE, Wagner BJ, Siegelman ES. Aggressive angiomyxoma: Findings on CT and MR imaging. Am J Roentgenol 1999;172:435-8.
13. Poirier M, Fraser R, Meterissian S. Unusual abdominal and pelvic tumors: Case 1. Aggressive angiomyxoma of the pelvis: response to luteinizing hormone-releasing hormone agonist. J Clin Oncol 2003;21:3535-6.
14. Fine BA, Munoz AK, Litz CE, Gershenson DM. Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist. Gynecol Oncol 2001;81:120-2.
15. Giles DL, Liu PT, Lidner TK, Maglibay PM. Treatment of aggressive angiomyxoma with aromatase inhibitor prior to surgical resection. Int J Gynecol Cancer 2008;18:375-9.
16. McCluggage WG, Jamieson T, Dobbs SP, Grey A. Aggressive angiomyxoma of the vulva: Dramatic response to gonadotropin-releasing hormone agonist therapy. Gynecol Oncol. 2006;100:623-5.
17. Schwartz PE, Hui P, McCarthy S. Hormonal therapy for aggressive angiomyxoma: a case report and proposed management algorithm. J Low Genit Tract Dis 2014;18:E355-61.
18. Beck AH, West RB, Van De Rijn M. Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Arch 2010;456:141-51.
19. Yang D, Yipáa A, Yang J, et al. An integrated study of aberrant gene copy number and gene expression in GIST and LMS. Technol Cancer Res Treat 2010;9:171-7.
20. Grossmann AH, Layfield LI, Randall RL. Classification, molecular characterization, and the significance of Pten alteration in leiomyosarcoma. Sarcoma. 2012;2012:380896.